On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical trial that assessed a new treatment plan for persons with resectable stage II (2), IIIA (3A), or IIIB (3B) NSCLC.

Individuals received Keytruda (pembrolizumab) with platinum-based chemotherapy prior to surgery (neoadjuvant treatment), followed by treatment with Keytruda (pembrolizumab) alone post-surgery (adjuvant treatment). Results showed that people given this treatment regimen showed a clinically meaningful benefit, including a longer period of time before progression or recurrence, compared to individuals who received only pre-operative platinum-based chemotherapy.

Read the full announcement from the FDA here.